New mRNA combo for lung cancer trial pulled before it began
Disease control
Terminated
This study aimed to test a new mRNA treatment (CVHNLC) plus the immunotherapy drug pembrolizumab in people with advanced squamous non-small-cell lung cancer. The goal was to find a safe dose and see if adding chemotherapy later could help control the disease. However, the trial w…
Phase: PHASE1 • Sponsor: CureVac • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC